vs
亚什兰（ASH）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Sotera Health Co的1.3倍（$386.0M vs $303.4M），Sotera Health Co净利率更高（11.5% vs -3.1%，领先14.6%），Sotera Health Co同比增速更快（4.6% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $52.4M），过去两年Sotera Health Co的营收复合增速更高（10.6% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
ASH vs SHC — 直观对比
营收规模更大
ASH
是对方的1.3倍
$303.4M
营收增速更快
SHC
高出9.3%
-4.7%
净利率更高
SHC
高出14.6%
-3.1%
自由现金流更多
ASH
多$58.6M
$52.4M
两年增速更快
SHC
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $303.4M |
| 净利润 | $-12.0M | $34.8M |
| 毛利率 | 27.2% | 54.7% |
| 营业利润率 | -1.6% | 23.2% |
| 净利率 | -3.1% | 11.5% |
| 营收同比 | -4.7% | 4.6% |
| 净利润同比 | 92.7% | 182.8% |
| 每股收益（稀释后） | $-0.26 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHSHC
| Q4 25 | $386.0M | $303.4M | ||
| Q3 25 | $477.0M | $311.3M | ||
| Q2 25 | $463.0M | $294.3M | ||
| Q1 25 | $479.0M | $254.5M | ||
| Q4 24 | $405.0M | $290.2M | ||
| Q3 24 | $521.0M | $285.5M | ||
| Q2 24 | $544.0M | $276.6M | ||
| Q1 24 | $575.0M | $248.2M |
净利润ASHSHC
| Q4 25 | $-12.0M | $34.8M | ||
| Q3 25 | $31.0M | $48.4M | ||
| Q2 25 | $-742.0M | $8.0M | ||
| Q1 25 | $31.0M | $-13.3M | ||
| Q4 24 | $-165.0M | $12.3M | ||
| Q3 24 | $17.0M | $17.0M | ||
| Q2 24 | $6.0M | $8.8M | ||
| Q1 24 | $120.0M | $6.3M |
毛利率ASHSHC
| Q4 25 | 27.2% | 54.7% | ||
| Q3 25 | 33.3% | 57.0% | ||
| Q2 25 | 28.5% | 56.6% | ||
| Q1 25 | 30.7% | 53.2% | ||
| Q4 24 | 27.4% | 56.6% | ||
| Q3 24 | 33.2% | 55.4% | ||
| Q2 24 | 34.2% | 55.2% | ||
| Q1 24 | 28.0% | 51.2% |
营业利润率ASHSHC
| Q4 25 | -1.6% | 23.2% | ||
| Q3 25 | 12.8% | 23.4% | ||
| Q2 25 | -152.9% | 6.4% | ||
| Q1 25 | 10.6% | -5.8% | ||
| Q4 24 | -44.2% | 30.0% | ||
| Q3 24 | 6.1% | 28.2% | ||
| Q2 24 | -11.2% | 27.8% | ||
| Q1 24 | 3.7% | 21.4% |
净利率ASHSHC
| Q4 25 | -3.1% | 11.5% | ||
| Q3 25 | 6.5% | 15.5% | ||
| Q2 25 | -160.3% | 2.7% | ||
| Q1 25 | 6.5% | -5.2% | ||
| Q4 24 | -40.7% | 4.2% | ||
| Q3 24 | 3.3% | 6.0% | ||
| Q2 24 | 1.1% | 3.2% | ||
| Q1 24 | 20.9% | 2.5% |
每股收益（稀释后）ASHSHC
| Q4 25 | $-0.26 | $0.12 | ||
| Q3 25 | $0.83 | $0.17 | ||
| Q2 25 | $-16.21 | $0.03 | ||
| Q1 25 | $0.65 | $-0.05 | ||
| Q4 24 | $-3.50 | $0.05 | ||
| Q3 24 | $0.34 | $0.06 | ||
| Q2 24 | $0.12 | $0.03 | ||
| Q1 24 | $2.39 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $344.6M |
| 总债务越低越好 | $1.4B | $2.1B |
| 股东权益账面价值 | $1.9B | $606.0M |
| 总资产 | $4.5B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.74× | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资ASHSHC
| Q4 25 | $304.0M | $344.6M | ||
| Q3 25 | $215.0M | $299.2M | ||
| Q2 25 | $207.0M | $332.4M | ||
| Q1 25 | $168.0M | $304.4M | ||
| Q4 24 | $219.0M | $277.2M | ||
| Q3 24 | $300.0M | $306.7M | ||
| Q2 24 | $399.0M | $246.1M | ||
| Q1 24 | $439.0M | $261.1M |
总债务ASHSHC
| Q4 25 | $1.4B | $2.1B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.4B | $2.2B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.3B | $2.2B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $1.3B | $2.2B | ||
| Q1 24 | $1.3B | $2.2B |
股东权益ASHSHC
| Q4 25 | $1.9B | $606.0M | ||
| Q3 25 | $1.9B | $550.5M | ||
| Q2 25 | $1.9B | $511.3M | ||
| Q1 25 | $2.6B | $414.1M | ||
| Q4 24 | $2.6B | $404.9M | ||
| Q3 24 | $2.9B | $470.2M | ||
| Q2 24 | $3.0B | $422.8M | ||
| Q1 24 | $3.1B | $429.4M |
总资产ASHSHC
| Q4 25 | $4.5B | $3.3B | ||
| Q3 25 | $4.6B | $3.2B | ||
| Q2 25 | $4.6B | $3.2B | ||
| Q1 25 | $5.2B | $3.1B | ||
| Q4 24 | $5.2B | $3.1B | ||
| Q3 24 | $5.6B | $3.1B | ||
| Q2 24 | $5.7B | $3.1B | ||
| Q1 24 | $5.9B | $3.1B |
负债/权益比ASHSHC
| Q4 25 | 0.74× | 3.53× | ||
| Q3 25 | 0.73× | 3.89× | ||
| Q2 25 | 0.73× | 4.34× | ||
| Q1 25 | 0.52× | 5.36× | ||
| Q4 24 | 0.51× | 5.49× | ||
| Q3 24 | 0.47× | 4.73× | ||
| Q2 24 | 0.45× | 5.26× | ||
| Q1 24 | 0.42× | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $52.4M |
| 自由现金流率自由现金流/营收 | 28.8% | 17.3% |
| 资本支出强度资本支出/营收 | 3.6% | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | $200.0M | $149.2M |
8季度趋势，按日历期对齐
经营现金流ASHSHC
| Q4 25 | $125.0M | $103.1M | ||
| Q3 25 | $40.0M | $71.2M | ||
| Q2 25 | $115.0M | $57.4M | ||
| Q1 25 | $9.0M | $55.5M | ||
| Q4 24 | $-30.0M | $55.7M | ||
| Q3 24 | $80.0M | $97.5M | ||
| Q2 24 | $127.0M | $61.3M | ||
| Q1 24 | $54.0M | $9.7M |
自由现金流ASHSHC
| Q4 25 | $111.0M | $52.4M | ||
| Q3 25 | $6.0M | $35.0M | ||
| Q2 25 | $95.0M | $26.2M | ||
| Q1 25 | $-12.0M | $35.6M | ||
| Q4 24 | $-53.0M | $-10.2M | ||
| Q3 24 | $42.0M | $61.1M | ||
| Q2 24 | $98.0M | $19.4M | ||
| Q1 24 | $20.0M | $-25.2M |
自由现金流率ASHSHC
| Q4 25 | 28.8% | 17.3% | ||
| Q3 25 | 1.3% | 11.2% | ||
| Q2 25 | 20.5% | 8.9% | ||
| Q1 25 | -2.5% | 14.0% | ||
| Q4 24 | -13.1% | -3.5% | ||
| Q3 24 | 8.1% | 21.4% | ||
| Q2 24 | 18.0% | 7.0% | ||
| Q1 24 | 3.5% | -10.2% |
资本支出强度ASHSHC
| Q4 25 | 3.6% | 16.7% | ||
| Q3 25 | 7.1% | 11.6% | ||
| Q2 25 | 4.3% | 10.6% | ||
| Q1 25 | 4.4% | 7.8% | ||
| Q4 24 | 5.7% | 22.7% | ||
| Q3 24 | 7.3% | 12.7% | ||
| Q2 24 | 5.3% | 15.2% | ||
| Q1 24 | 5.9% | 14.1% |
现金转化率ASHSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | 1.29× | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | 4.71× | 5.73× | ||
| Q2 24 | 21.17× | 7.00× | ||
| Q1 24 | 0.45× | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
